Replies to post #142365 on Biotech Values

[vinmantoo]

Dew,

<This is not a hugely important indication from a commercial standpoint because there are relatively few NSCLC patients left by the time they have failed two or more other treatments.>

I didn't read anything stating the that patients in the trial had their tumors genotyped for mutations such as KRAS. One might think that using KRAS patients makes sense given the MOA of Nexavar. Was the omission likely due to the small numbers of such patients alive after two or more treatment?